Antibe Therapeutics Inc. (OTCMKTS:ATBPF – Get Rating) – Research analysts at Zacks Small Cap upped their FY2023 EPS estimates for shares of Antibe Therapeutics in a report issued on Wednesday, September 7th. Zacks Small Cap analyst D. Bautz now forecasts that the company will post earnings of ($0.35) per share for the year, up from their previous estimate of ($0.36). The consensus estimate for Antibe Therapeutics' current full-year earnings is ($0.31) per share.

Separately, Brookline Capital Management reaffirmed a "buy" rating on shares of Antibe Therapeutics in a research report on Thursday, June 30th.

Antibe Therapeutics Price Performance

Antibe Therapeutics Company Profile

(Get Rating)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

Read More

• Get a free copy of the StockNews.com research report on Antibe Therapeutics (ATBPF)
• Can Electronic Arts Buck the Downturn in Videogaming?
• Dollar General is the Big Fish in Little Ponds Across the U.S.
• Here's Why the CPI Report will Dictate the Market Bottom
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.